внебольничная пневмонияантимикробная терапияантибактериальная терапия1.Биличенко Т.Н., Чучалин А.Г., Сон И.М. Основные итоги развития специализированной медицинской помощи больным пульмонологического профиля на территории Российской Федерации за период 2004–2010 гг. Пульмонология. 2012; 3: 5–16.2.Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2010.3.http://www.who.int/gho/mortality_burden_disease/causes_death_2008/en/index.html.4.Colice G.L., Morley M.A., Asche C et al. Treatment costs of community - acquired pneumonia in an employed population. Chest 2004; 125 (6): 2140–45.5.Niederman M.S., Mandell L.A., Anzueto A et al. Guidelines for the management of adults with community - acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730–54.6.Bartlett J.G., Dowell S.F., Mandell L.A. et al. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community - acquired pneumonia in adults. Clin Infect Dis 2000; 31 (2): 347–82.7.File T.M. The Science of Selecting Antimicrobials for Community-Acquired Pneumonia (CAP). J Manag Care Pharm 2009;15 (2) (Suppl.): S5–S11.8.Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low - risk patients with community - acquired pneumonia. N Engl J Med 1997; 336 (4): 243–50.9.Lim W.S., van der Eerden M.M., Laing R et al. Defining community - acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (5): 377–82.10.Capelastegui A, Espana P.P., Quintana J.M. et al. Validation of a predictive rule for the management of community - acquired pneumonia. Eur Respir J 2006; 27 (1): 151–57.11.Herrera-Lara S, Fernández-Fabrellas E, Cervera-Juan A, Blanquer-Olivas R. Do Seasonal Changes and Climate Influence the Etiology of Community Acquired Pneumonia? Arch Bronconeumol 2013; pii: S0300–2896 (12) 00310-9. doi: 10.1016/j.arbres.2012.11.001. [Epub ahead of print].12.Kurutepe S, Ecemiş T, Ozgen A et al. Investigation of bacterial etiology with conventional and multiplex PCR methods in adult patients with community - acquired pneumonia. Mikrobiyol Bul 2012; 46 (4): 523–31.13.Tao L.L., Hu B.J., He L.X. et al. Etiology and antimicrobial resistance of community - acquired pneumonia in adult patients in China. Chin Med J (Engl.) 2012; 125 (17): 2967–72.14.Рачина С.А. Фармакоэпидемиологические, фармакоэкономические и фармакотерапевтические подходы к ведению пациентов с внебольничной пневмонией в стационаре. Дис.. д-ра мед. наук. Смоленск, 2010.15.Mandell L.A., Marrie T.J., Grossman R.F.et al. Summary of Canadian Guidelines for the Initial Management of Community - acquired Pneumonia: An evidence - based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis 2000; 11 (5): 237–48.16.Mandell L.A., Wunderink R.G., Anzueto A et al. Infectious Diseases Society of America and American Thoracic Society. Infectious Diseases Society of America. American Thoracic Society consensus guidelines on the management of community - acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–S72.17.Clavo-Sanchez A.J., Giron-Gonzalez J.A., Lopez-Prieto D et al. Multivariate analysis of risk factors for infection due to penicillin - resistant and multidrug - resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24 (6): 1052–9.18.Vanderkooi O.G., Low D.E., Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40 (9): 1288–97.19.Harwell J.I., Brown R.B. The drug - resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 2000; 117 (2): 530–41.20.Синопалыников А.И., Гучев И.А. Азитромицин (Сумамед): лекарственная форма для внутривенного введения. Клин. фармакология и терапия. 2004; 5: 9–15.21.Olsen K, San Pedro G, Gann L et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40: 2582–5.22.Gladue R, Bright G, Isaacson R, Newborn M. In vitro and in vivo uptake of azithromycin (CP 62,993) by phagocytic cells: possible mechanism of delivery and release at site of infection. Antimicrob Agents Chemother 1989; 33: 277–82.23.Foulds G, Shepard R, Johnson R. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25: 73–82.24.Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. New York, 1995; p. 51–60.25.Rapp R.P. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Аnn Pharmacother 1998; 32 (7–8): 785–93.26.Treadway G, Pontani D. Paediatric savety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37 (Suppl. C): 143–9.27.Ioannidis J, Contopoulos-Ioannidis D, Chew P, Lau J. Meta - analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. J Antimicrob Chemoter 2001; 48: 677–89.28.Zimmermann T, Riedel K, Laufen H et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans 1996: A82.29.Vergis E.N., Indorf A, File T.M. et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community - acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160: 1294–300. 226.30.Plouffe J, Schwartz D.B., Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community - acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44: 1796–802.31.Feldman R.B., Rhew D.C., Wong J.Y. et al. Azithromycin monotherapy for patients hospitalized with community - acquired pneumonia: a 3 1/2-year experience from a veterans affairs hospital. Arch Intern Med 2003; 163: 1718–26.32.Leroy O, Saux P, Bedos J.P., Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community - acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–83.33.Gleason P.P., Meehan T.P., Fine J.M. et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159 (21): 2562–72.34.Burgess D.S., Lewis J.S. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community - acquired pneumonia. Clin Ther 2000; 22 (7): 872–8.35.Houck P.M., MacLehose R.F., Niederman M.S., Lowery J.K. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995 and 1997. Chest 2001; 119 (5): 1420–6.36.Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161 (15): 1837–42.37.Brown R.B., Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community - acquired pneumonia: analysis of a hospital claims - made database. Chest 2003; 123 (5): 1503–11.38.Metersky M.L., Ma A, Houck P.M., Bratzler D.W. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131 (2): 466–73.39.Tessmer A, Welte T, Martus P et al. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community - acquired pneumonia. J Antimicrob Chemother 2009; 63 (5): 1025–33.40.Martinez J et al. Addition of a macrolide to a beta - lactam - based empirical antibiotic regimen is associated with lower in - hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389–95.41.Dudas V, Hopefl A, Jacobs R, Guglielmo B.J. Ann Pharmacother. Antimicrobial selection for hospitalized patients with presumed community - acquired pneumonia: a survey of nonteaching US community hospitals. 2000; 34 (4): 446–52.42.Baddour L.M., Yu V.L., Klugman K.P. et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170 (4): 440–4.43.Asadi L, Sligl W.I., Eurich D.T. et al. Macrolide - based regimens and mortality in hospitalized patients with community - acquired pneumonia: a systematic review and meta - analysis. Clin Infect Dis 2012; 55 (3): 371–80.44.Zarogoulidis P, Papanas N, Kioumis I et al. Macrolides: from in vitro anti - inflammatory and immunomodulatory properties to clinical practice in respiratory diseases [published online ahead of print 22 November 2011]. Eur J Clin Pharmacol 2011.45.Amsden G.W. Anti - inflammatory effects of macrolides – an underappreciated benefit in the treatment of community - acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10–21.46.Синопальников А.И., Дуганов В.К. Левофлоксацин: ступенчатая терапия внебольничной пневмонии у взрослых. РМЖ. 2001; 9 (15): 650–5.47.Fine A, Grossman R, Ost D, Farber B, Cassiere H. Diagnosis and Management of Pneumonia and Other Respiratory Infections. 1st ed. Berlin: PCI, 1999.48.Страчунский Л.С., Розенсон О.Л. Ступенчатая терапия: новый подход к применению антибактериальных препаратов. Клин. фармакология и терапия. 1997; 6: 15–24.49.Rhew D.C., Tu G.S., Ofman J et al. Early switch and early discharge strategies in patients with community - acquired pneumonia: a meta - analysis. Arch Intern Med 2001; 161 (5): 722–7.50.Weingarten S.R., Reidinger M.S., Varis G et al. Identification of low - risk hospitalized patients with pneumonia: implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109–15.51.Plouffe J, Schwartz D.B., Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community - acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44 (7): 1796–802.52.Paladino J.A., Gudgel L.D., Forrest A, Niederman M.S. Cost - effectiveness of IV - to - oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community - acquired pneumonia. Chest 2002; 122 (4): 1271–9.53.Zervos M, Mandell L.A., Vrooman P.S. et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step - down oral therapy for hospitalized patients with moderate to severe community - acquired pneumonia. Treat Respir Med 2004; 3 (5): 329–36.54.Tamm M, Todisco T, Feldman C et al. Clinical and bacteriological outcomes in hospitalised patients with community - acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect 2007; 13 (2): 162–71.55.Синопальников А.И., Зайцев А.А. Азитромицин в пульмонологической практике:лет спустя. Справ. поликлин. врача. 2009; 10: 38–43.